Who regulates supplement claims, the FDA or the FTC, and what neither of them checks

Who regulates what a supplement says about itself?

The FDA and the FTC divide it. The FDA states that it is generally responsible for supplement safety, quality and labeling, while the FTC is generally responsible for advertising. Both agencies can bring enforcement actions against the same product. Neither operates a desk that reviews and clears a claim before the product goes on sale.

The split is written into the FDA’s own consumer Q&A on dietary supplements. It sounds tidier than it is in practice. The FTC’s working definition of advertising expressly includes packaging and labeling, so the bottle in your hand sits inside both agencies’ jurisdiction at the same time.

What matters more is the timing. The FDA’s authority over a supplement begins after the product reaches the market, according to the agency’s own dietary supplements overview. The FTC’s involvement typically begins when someone complains or when an investigator picks the product up.

One related label phrase causes constant confusion. Facilities that manufacture, process, pack or hold supplements for US consumption must register with the FDA under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. That is a filing obligation, not a quality review, and the difference is unpacked in FDA registered versus FDA approved.

If the product is a wellness device rather than a supplement, the vocabulary changes again, and cleared does not mean approved. That distinction is covered in FDA cleared versus FDA approved.

Does anyone check the claim before the product goes on sale?

No. Under DSHEA, the Dietary Supplement Health and Education Act of 1994, the FDA does not have authority to approve dietary supplements before they are marketed, and generally does not approve supplement claims or labeling before use. Manufacturers and distributors evaluate their own safety and labeling. Nothing is filed for review first.

Three separate federal bodies say this in plain language. The FDA states that “by statute, the FDA does not approve dietary supplements for safety and effectiveness” and that “many dietary supplements can be marketed without even notifying the FDA,” in its consumer update Is It Really “FDA Approved”?. NIH’s NCCIH states the agency is “not authorized to review dietary supplements for safety and effectiveness before they are marketed.” NIH’s Office of Dietary Supplements states the FDA “does not determine whether dietary supplements are effective before they are marketed.”

The consequence runs deeper than approval. Because there is no premarket step, the FDA says it “often does not know when new products come on the market” and cannot maintain a complete list of the supplements sold in the United States.

What is a structure/function claim and why does almost every bottle carry one?

A structure/function claim is a statement that an ingredient affects the normal structure or function of the human body, which the manufacturer must be able to substantiate but never has to prove to the FDA before printing it. It is the widest lane available, so almost every product uses it.

The FDA’s rule is that a firm making a structure/function claim “must have substantiation that the claim is truthful and not misleading.” The substantiation is never filed with the agency and never reviewed by it. It sits in a drawer at the company.

The only filing requirement is a notification, and it runs the wrong way round for a consumer. Under 21 CFR 101.93(a), the firm must notify the FDA no later than 30 days after first marketing a supplement bearing a structure/function claim, and certify that it holds substantiation. The product is already on shelves when the paperwork arrives. The FDA does not evaluate the evidence in response.

The FDA’s own permitted examples show how modest the permitted wording is: “calcium builds strong bones,” “fiber maintains bowel regularity,” “antioxidants maintain cell integrity.”

What turns a legal claim into an illegal drug claim?

Naming a disease, or implying one. Under 21 CFR 101.93(f), a product marketed as a supplement that bears a disease claim “will be subject to regulation as a drug unless the claim is an authorized health claim for which the product qualifies.” Ten separate criteria in the regulation define what counts.

The regulation defines disease as damage to an organ, part, structure or system such that it does not function properly, or a state of health leading to that dysfunction. Cardiovascular disease and hypertension are the FDA’s own examples. Essential-nutrient deficiency diseases such as scurvy and pellagra are excluded.

The detail almost nobody writes about is how many ways a disease claim can be created. Under 21 CFR 101.93(g)(2), a statement is a disease claim if it conveys the effect explicitly or implicitly, and the regulation lists the product’s name, the publications it cites, and its pictures, vignettes and symbols among the triggers. A product called “Arthrocure” makes a disease claim through its name alone. So does a bottle carrying a citation to a hypertension trial, or an illustration of an inflamed joint.

That fourth column is the part worth holding onto. The osteoporosis wording is legal, but only because the FDA authorized it by regulation under the significant scientific agreement standard, as set out in the agency’s guide to label claims for conventional foods and dietary supplements. Health claims are the one supplement claim category that does get reviewed before use. They are rare.

Why does the label say the FDA has not evaluated this?

Because a structure/function claim was made. The disclaimer is not generic legal boilerplate applied to every bottle. It is a specific consequence, required by 21 CFR 101.93(c), that attaches when the manufacturer chooses to say something about structure or function. Its presence tells you which lane the claim is in.

The required single-claim text is exact: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” The plural form reads “These statements have not been evaluated by the Food and Drug Administration,” followed by the same second sentence.

The formatting is prescribed too. Under 21 CFR 101.93(d) and (e), the disclaimer must appear in boldface type no smaller than one-sixteenth inch, adjacent to the claim or linked to it by a symbol, and boxed where it is not adjacent.

Read it as a signal, not as small print. It means the company made a claim it was allowed to make without showing anyone the evidence. Conventional foods carry no such disclaimer and trigger no notification, because those rules are supplement-specific.

What does the FTC require an advertiser to actually hold?

Competent and reliable scientific evidence. The FTC’s Health Products Compliance Guidance sets this as the substantiation standard for health benefit and safety claims. It is a documentation duty the advertiser must satisfy before publishing, though no agency inspects the file first.

The FTC defines the standard as “tests, analyses, research, or studies that (1) have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function” and “(2) are generally accepted in the profession to yield accurate and reliable results.” The evidence must also be “sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields, when considered in light of the entire body of relevant and reliable scientific evidence.”

That last clause matters. Cherry-picking one favourable trial out of a mixed literature does not meet the standard. And the FTC is explicit about study design: “as a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing.”

This is the standard behind the phrase readers see most often, and it is why “clinically proven” on a supplement label carries a heavier legal load than most buyers assume.

What counts as advertising under FTC rules?

Far more than a television spot. The FTC’s definition expressly includes packaging and labeling, brochures, websites, social media, influencer marketing, press releases and interviews, trade shows, and promotion made indirectly through healthcare practitioners. If a claim reaches a buyer through any of those, the FTC substantiation standard applies to it.

Two entries in that list deserve attention. Influencer marketing is advertising, so a claim made in a paid creator’s video carries the same substantiation requirement as one printed on the box. The advertiser must hold the evidence, not the influencer.

Promotion through healthcare practitioners is the one most buyers never suspect. A supplement sold or recommended in a clinic, with brand literature supplied by the manufacturer, is being advertised. The clinical setting does not create an exemption.

This is also why the FDA and FTC lanes overlap rather than sit side by side. The label is FDA territory for its content and FTC territory as advertising. One printed sentence can be actionable by either agency.

What happens when a company gets it wrong?

Enforcement comes after publication, and it is not rare in absolute terms. The FTC states that since 1998 it has settled or adjudicated more than 200 cases involving false or misleading advertising claims about the benefits or safety of dietary supplements or other health-related products. That is a substantial record spread across decades and a very large market.

Set that number against the scale. US sales of dietary supplements totaled an estimated $55.7 billion in 2020, according to NIH ODS, and 57.6% of US adults aged 20 and over reported using a supplement in the past 30 days in NHANES 2017-2018 data published by CDC/NCHS. More than 200 cases across that market is a filter, not a net.

A reader can add to the record. Deceptive advertising complaints go to the FTC at ReportFraud.ftc.gov. Problems with a product itself, including labeling and adverse events, go to the FDA through its Safety Reporting Portal. Both are the mechanism by which a bad claim actually gets found.

So who actually checks?

In practice, almost nobody, and never before the claim is printed. The FDA does not review it in advance. The FTC does not review it in advance. Voluntary testers check contents, not claims. The real check is retrospective, complaint-driven, and applied to a small fraction of products.

Here is the judgement. The strongest signal available to a buyer is not the claim and not the disclaimer. It is third-party verification of what is actually in the bottle, because that is the one thing an independent body genuinely tests. USP and NSF audit facilities and test samples against declared potency and contaminant limits, which is why third-party tested supplements are worth distinguishing from the rest.

But even that is a narrower guarantee than it looks. NIH ODS states plainly that quality seals from third-party testers “do not guarantee that a product is safe or effective.” Verification tells you the label is accurate about contents. It says nothing about whether the ingredient does what the front of the box says.

So the working rule is this. Treat the disclaimer as a marker that a claim was made without review. Treat “clinically proven” as a promise the marketer is legally obliged to be able to document, then ask whether they have. And treat any decision about taking, stopping or changing a supplement as one to make with a licensed clinician who knows your history.

The method behind how these claims are checked against primary sources is set out in how we research.